Biblio
Decitabine in combination with idarubicin within a modified busulfan/cyclophosphamide conditioning regimen for patients with advanced myelodysplastic syndrome: A prospective multicenter clinical cohort study. Chin Med J (Engl). 2024.
Exploring strategies to optimise outcomes in hepatitis-associated aplastic anaemia patients following haematopoietic stem cell transplantation. Sci Rep. 2024;14(1):5178.
Outcomes of acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: validation, comparison and improvement of 2022 ELN genetic risk system. Exp Hematol Oncol. 2024;13(1):16.
Ursodeoxycholic acid does not reduce SARS-CoV-2 infection in newly allogeneic hematopoietic stem cell transplantation recipients: a prospective NICHE cohort. Front Cell Infect Microbiol. 2024;14:1324019.
Application of prophylactic or pre-emptive therapy after allogeneic transplantation for high-risk patients with t(8;21) acute myeloid leukemia. Hematology. 2023;28(1):2205739.
Application prospect of low-dose porcine anti-thymocyte globulin in HLA-matched sibling donor transplantation. Hematology. 2023;28(1):2212943.
The Composite Immune Risk Score predicts overall survival after allogeneic hematopoietic stem cell transplantation: A retrospective analysis of 1838 cases. Am J Hematol. 2023.
Explorations of post-gDLI low-dose cyclophosphamide for preventing severe aGVHD. Int Immunopharmacol. 2023;125(Pt A):111165.
The outcome of acute leukemia patients with SET-NUP214 fusion after allogeneic stem cell transplantation. Front Oncol. 2023;13:1256043.
Higher Dose of CD34 cells Promotes Early Reconstitution of Natural Killer Cells and Is Associated with Better Outcomes After Unmanipulated Hematopoietic Stem Cell Transplantation for Myeloid Malignancies. Transplant Cell Ther. 2022.
Primary graft failure following allogeneic hematopoietic stem cell transplantation: risk factors, treatment and outcomes. Hematology. 2022;27(1):293-299.